These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30773411)

  • 1. Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.
    Phillips RH; Salzman M; Haroz R; Rafeq R; Mazzarelli AJ; Pelletier-Bui A
    Ann Emerg Med; 2019 Sep; 74(3):430-432. PubMed ID: 30773411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.
    D'Amore A; Romano F; Biancolillo V; Lauro G; Armenante C; Pizzirusso A; Del Tufo S; Ruoppolo C; Auriemma F; Cassese F; Oliva P; Amato P
    Clin Drug Investig; 2012 Jul; 32(7):427-32. PubMed ID: 22559256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
    Strain EC; Harrison JA; Bigelow GE
    Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder.
    Herring AA; Schultz CW; Yang E; Greenwald MK
    Am J Emerg Med; 2019 Dec; 37(12):2259-2262. PubMed ID: 31239086
    [No Abstract]   [Full Text] [Related]  

  • 7. Commercial factors override science in combination addiction drug trial.
    Byrne A
    Clin Pharmacol Ther; 2011 Nov; 90(5):649; author reply 650. PubMed ID: 21956617
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
    Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
    Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
    Chhabra N; Aks SE
    Am J Emerg Med; 2020 Mar; 38(3):691.e3-691.e4. PubMed ID: 31753622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
    Caldiero RM; Parran TV; Adelman CL; Piche B
    Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
    González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
    Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan.
    Nagano T; Kimoto S; Aso K; Komori T; Yamaguchi Y; Okamura K; Yamamoto N; Kishimoto T
    Neuropsychopharmacol Rep; 2020 Dec; 40(4):376-382. PubMed ID: 33107693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
    Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.